p53 mutations in human cancers
- PMID: 1905840
- DOI: 10.1126/science.1905840
p53 mutations in human cancers
Abstract
Mutations in the evolutionarily conserved codons of the p53 tumor suppressor gene are common in diverse types of human cancer. The p53 mutational spectrum differs among cancers of the colon, lung, esophagus, breast, liver, brain, reticuloendothelial tissues, and hemopoietic tissues. Analysis of these mutations can provide clues to the etiology of these diverse tumors and to the function of specific regions of p53. Transitions predominate in colon, brain, and lymphoid malignancies, whereas G:C to T:A transversions are the most frequent substitutions observed in cancers of the lung and liver. Mutations at A:T base pairs are seen more frequently in esophageal carcinomas than in other solid tumors. Most transitions in colorectal carcinomas, brain tumors, leukemias, and lymphomas are at CpG dinucleotide mutational hot spots. G to T transversions in lung, breast, and esophageal carcinomas are dispersed among numerous codons. In liver tumors in persons from geographic areas in which both aflatoxin B1 and hepatitis B virus are cancer risk factors, most mutations are at one nucleotide pair of codon 249. These differences may reflect the etiological contributions of both exogenous and endogenous factors to human carcinogenesis.
Similar articles
-
1995 Deichmann Lecture--p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology and cancer risk assessment.Toxicol Lett. 1995 Dec;82-83:1-7. doi: 10.1016/0378-4274(95)03643-1. Toxicol Lett. 1995. PMID: 8597035 Review.
-
Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations.Cancer Res. 1991 Aug 1;51(15):4102-6. Cancer Res. 1991. PMID: 1855226
-
High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.Cancer Res. 1999 Aug 1;59(15):3634-40. Cancer Res. 1999. PMID: 10446974
-
p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China.Cancer Res. 1994 Aug 15;54(16):4342-6. Cancer Res. 1994. PMID: 8044781
-
p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment.Environ Health Perspect. 1996 May;104 Suppl 3(Suppl 3):435-9. doi: 10.1289/ehp.96104s3435. Environ Health Perspect. 1996. PMID: 8781359 Free PMC article. Review.
Cited by
-
Novel 9-Methylanthracene Derivatives as p53 Activators for the Treatment of Glioblastoma Multiforme.Molecules. 2024 May 19;29(10):2396. doi: 10.3390/molecules29102396. Molecules. 2024. PMID: 38792257 Free PMC article.
-
Zinc and Its Antioxidant Properties: The Potential Use of Blood Zinc Levels as a Marker of Cancer Risk in BRCA1 Mutation Carriers.Antioxidants (Basel). 2024 May 16;13(5):609. doi: 10.3390/antiox13050609. Antioxidants (Basel). 2024. PMID: 38790714 Free PMC article.
-
Comprehensive Bioinformatic Investigation of TP53 Dysregulation in Diverse Cancer Landscapes.Genes (Basel). 2024 Apr 30;15(5):577. doi: 10.3390/genes15050577. Genes (Basel). 2024. PMID: 38790205 Free PMC article.
-
Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal Transduct Target Ther. 2024 May 20;9(1):132. doi: 10.1038/s41392-024-01823-2. Signal Transduct Target Ther. 2024. PMID: 38763973 Free PMC article. Review.
-
Metabolic signature and response to glutamine deprivation are independent of p53 status in B cell malignancies.iScience. 2024 Mar 28;27(5):109640. doi: 10.1016/j.isci.2024.109640. eCollection 2024 May 17. iScience. 2024. PMID: 38680661 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous